Over that past few weeks I have read many articles and heard patients describe their feelings of having to deal with a cancer diagnosis and treatment in the time of COVID-19. A few days ago I read an article in Reuters about how medical testing and cancer screenings have dropped since the outbreak.
I am pleased to share this guest post by Mira Hellmann MD, Gynecologic Oncologist, Regional Cancer Care Associates, Hackensack University Medical Center on Cancer Care in the Time of COVID-19.
I am pleased to share this guest post by Mira Hellmann MD, Gynecologic Oncologist, Regional Cancer Care Associates, Hackensack University Medical Center on Cancer Care in the Time of COVID-19.
The WHO (World Health Organization) declared
the Coronavirus outbreak a pandemic on
3/11/2020. This led to immediate action around the world aimed at decreasing
the spread of infection.Many different recommendations have emerged regarding
safety and precautions that are necessary in order to slow the spread of the
pandemic and to save as many lives as possible. Furthermore, fears of
collapsing the healthcare systems resulted in recommendations that reserved
much of the system’s resources for management of patients diagnosed with
COVID-19. Various cancer societies around the world put together suggested
guidelines regarding the care and management of cancer patients during this
pandemic. These recommendations were derived from data from China that
indicated a significantly higher risk of coronavirus in patients with active cancer,
and potentially in patients with a history of cancer. In some reports cancer
was noted to be present in up to 20% of coronavirus infected patients.
Mortality also appeared to be higher in active cancer patients, with a
mortality rate of 2.3% in the overall population versus 5.6% in the active
cancer patient population. These recommendations resulted in a precipitous drop
in patient visits to the doctor. For patients who do present for treatment,
modifications to standard treatments were recommended, such as withholding
surgical or chemotherapy interventions in slower growing cancers, and modifying
management in more aggressive cancers including increasing use of outpatient
therapies and non cytotoxic therapies in lieu of surgery or cytotoxic chemotherapy.
This started six weeks ago. We have now
learned more about the disease, its pattern of spread, and most importantly its
anticipated trajectory. As more data emerges the likelihood of this pandemic
ending abruptly; and thereby resulting in a rapid reopening of all services and
resumption of normal standard of care,
is rapidly decreasing. As time progresses, the concern for rising rates
of adverse non COVID outcomes, such as cancer, become more acute. Some have
dubbed this the distraction effect. The
extent of this effect is currently unmeasured, but with further delay in care
the magnitude of this effect will continue to grow. According to the American
Cancer Society 5,000 new cancer cases are diagnosed daily in the US. Given the
current restrictions with access to health care, many of these cancers are
going undiagnosed. Many cancers, including ovarian cancer and high grade
endometrial cancer, as well as other solid and liquid tumors, are time sensitive in terms of treatment urgency and its effects on cancer
outcomes. According to a report published in Reuters 4/28/2020 rates of
screening tests for various cancers, including cervical cancer, have plummeted in the United States since mid
March, with a notable drop of 68% nationally, and even higher in coronavirus
hotspots. Since we have gained more insight into the disease, we have managed
to institute measures that increase safety of delivery of care, at the same
time avoiding compromising the quality of the care. Universal masking measures,
both for patients as well as providers, symptoms screening, including screening
of contacts, and more readily available swab testing, amongst many other
measures, have dramatically improved the safety of delivery of care.
Telehealth, although useful in some situations, lacks physical exam, which is
integral to evaluating gynecologic
malignancies. I am urging all patients
to be proactive about their cancer care, and ensure that they are not having
their cancer care compromised. Please go
to your doctor, or find a doctor who will see you. Please do not allow fear to
interfere with your health care.
Stay healthy, stay safe.
Thank you Dr Hellmann.
Dee Sparacio
Every Day is a Blessing!
Mira Hellmann MD
Gynecologic Oncologist, Regional Cancer Care
Associates, Hackensack University Medical Center
Thank you Dr Hellmann.
Dee Sparacio
Every Day is a Blessing!